Cantor Fitzgerald reiterates positive rating on Taysha for strong clinical data

From Yahoo Finance: 2025-06-29 03:03:00

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 best healthcare penny stocks to buy according to analysts. Cantor Fitzgerald reiterated its “Overweight” rating and $13.00 price target for Taysha on June 13. The company focuses on developing AAV-based gene therapies for rare monogenic diseases of the central nervous system, including TSHA-102 for Rett syndrome.

Cantor Fitzgerald reaffirmed its positive stance on Taysha based on recent positive Phase 1/2 clinical data for TSHA-102, an adeno-associated virus (AAV)-based gene therapy. The analysts also noted strong positive sentiment among stakeholders, including investors and key opinion leaders. However, they acknowledged that this sentiment was not reflected in the stock’s current market valuation.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing gene therapies for central nervous system disorders. Its lead programs include TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy, among others. The company aims to address rare monogenic diseases such as CLN1, CLN7, and Angelman syndrome through its innovative treatments.



Read more at Yahoo Finance: Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical Data